Trusted by leading pharma companies and medical institutes
Combine the power of clinical data and innovative algorithms
HopeAI is on a mission to accelerate clinical development using the power of comprehensive clinical evidence, cutting-edge statistical innovations, and AI technology. We are addressing the challenges in longer trials with large sample size, inefficient statistical study designs, slow patient recruitment, and high cost of control arms. We have curated a comprehensive evidence database and developed innovative algorithms to solve these challenges. Our core solutions include PURE Evidence - latest clinical evidence, SynthIPD - synthetic patient data derived from real clinical studies and CARA Design - adaptive design for precision medicine. Join top life science companies in partnering with HopeAI to optimize clinical trial design, improve patient recruitment, increase the probability of success, and accelerate clinical development timeline.
PURE Evidence
- Precise - Covering both study-level and subgroup-level clinical outcome
- Up-to-date - Covering both primary and follow-up publications
- Reliable - Curated by clinical scientists, standardized by statisticians
- Easily accessible - Readily available through natural language
- Synthetic individual patient data generated by AI based on real clinical trial results
- Provides a practical and cost-effective way to access individual-level clinical trial data while safeguarding privacy
- Enable the design of smaller and more targeted trials and shorten the drug development timeline
SynthIPD
CARA Design
- Covariate-adjusted response adaptive randomization for precision medicine
- Increase the chance of patients being randomized to superior treatments
- Make the trial more competitive, attractive and accelerate patient recruitment
Clinical teams use PURE Evidence and SynthIPD to establish surrogate endpoints
In collaboration with Mayo Clinic, Fred Hutch Cancer Center and Takeda
The association between MRD negativity and survival endpoints in multiple myeloma was validated using AI-powered clinical evidence. A prior project led by our collaborators resulted in the FDA's approval of MRD as an endpoint for accelerated approval. Now, with our PURE Evidence and SynthIPD, we can deliver more comprehensive and up-to-date association analyses at both the trial and patient levels in weeks, rather than years.
Oncologists use HopeAI for evidence-based medicine
In partnership with HemOnc.org, the world's largest medical wiki of treatment information for hematology and oncology
Utilizing the best aspects of human expertise and AI to address the unmet need for reliable clinical evidence, our AI Copilot enables oncologists to gain deep insights into treatment regimens and their supporting clinical trials by simply asking questions. An AI-driven workflow, combined with expert curation, ensures the accuracy and relevance of the answers.
Our Mission